Table 4 Clinicopathological characteristics of long-term survivors and non-survivors

Age, year, median (range)

59 (33–75)

58 (24–80)

0.429

Gender, n (%)

0.287

 Male

12 (36.4)

94 (46.3)

 Female

21 (63.6)

109 (53.7)

Timing of PM, n (%)

0.003

0.018

 Synchronous

7 (21.2)

100 (49.3)

Reference

 Metachronous

26 (78.8)

103 (50.7)

3.10 (1.14, 8.39)

Primary tumor location, n (%)

0.753

 Right colon

16 (48.5)

102 (50.3)

 Left colon

17 (51.5)

98 (48.3)

 Rectum

0 (0)

3 (1.5)

Histology, n (%)

0.036

< 0.001

 tub

23 (69.7)

128 (63.1)

11.86 (2.88, 48.82)

 muc

8 (24.2)

27 (13.3)

Reference

 por or sig

2 (6.1)

48 (23.7)

0.031 (0.004, 0.228)

Lymph node metastasis, n (%)

0.553

 Negative

13 (39.4)

67 (33.0)

 Positive

20 (60.6)

136 (67.0)

PCI at CRS, median (range)

4 (1–27)

9 (0–39)

< 0.001

0.001 (1.68E−05, 0.055)

< 0.001

Completeness of cytoreduction, n (%)

< 0.001

< 0.001

 CCR-0

33 (100)

141 (69.8)

Reference

 CCR-1 to 3

0 (0)

61 (30.2)

8.19E + 07 (0.00, -)

HIPEC, n (%)

0.407

 Yes

26 (78.8)

142 (70.0)

 No

7 (21.2)

61 (30.1)

Postoperative complocation (G ≥ 3), n (%)

0.199

 Yes

5 (15.2)

53 (26.2)

 No

28 (84.9)

150 (73.9)

0.147

 Yes

28 (84.9)

190 (93.6)

 No

5 (15.2)

13 (6.4)

Postoperative chemotherapy, n (%)

0.820

 Yes

27 (81.8)

158 (77.8)

 No

6 (18.2)

45 (22.2)